8-K: Hologic Receives Regulatory Approval for Go-Private Deal

Hologic has secured all necessary regulatory approvals for its acquisition by Blackstone and TPG, with the transaction expected to close on April 7, 2026.

Summary

• Hologic has received all required regulatory approvals to complete its acquisition by affiliates of Blackstone Inc. and TPG Global, LLC.
• The transaction is expected to close on or about April 7, 2026, subject to customary closing conditions.
• CEO Stephen P. MacMillan will retire from his roles as President, CEO, and Chairman immediately following the closing of the merger.
• The company reported significant historical growth under MacMillan's 12-year tenure, including a 65% increase in revenue and a 241% increase in share price.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development for shareholders, as the company has successfully navigated the regulatory process to finalize a premium-priced acquisition.

Positives

• Receipt of all necessary regulatory approvals for the merger.
• Strong historical performance under outgoing CEO Stephen P. MacMillan, including 184% growth in non-GAAP EPS.
• Successful transition to a private entity under Blackstone and TPG ownership.

Negatives

• Departure of long-time CEO Stephen P. MacMillan upon the closing of the transaction.
• Transition to private ownership removes the company from public equity markets.

Risks

• Potential failure to satisfy remaining customary closing conditions before the expected April 7, 2026 date.
• Risk that CVR holders receive less-than-anticipated payments post-closing.
• Potential disruption to business operations and management focus during the final stages of the merger.
• Uncertainty regarding the retention of key personnel and maintenance of business relationships post-acquisition.

Future Outlook

The company is transitioning to private ownership under Blackstone and TPG, with the transaction expected to finalize on or about April 7, 2026. A new CEO is expected to be announced upon the closing of the deal.

Management Comments

• Amy Wendell, Lead Independent Director: 'Hologic's board of directors, and all the Company's stakeholders, owe a debt of gratitude to Steve, one of the most respected leaders in the medical technology industry.'
• Stephen P. MacMillan, CEO: 'Leading Hologic has been the greatest honor and privilege of my career... I know they will make even greater contributions to women's health as a private firm owned by Blackstone and TPG.'

Industry Context

StockSavvy.ai notes that this transaction represents a significant consolidation in the medical technology sector, reflecting a broader trend of private equity firms acquiring established, high-growth healthcare companies to drive long-term value away from public market volatility.

Comparison to Industry Standards

• The 241% share price growth over 12 years significantly outperforms many standard medical device benchmarks for the same period.
• The transition to private equity ownership is consistent with recent trends seen in the med-tech space, similar to other large-scale take-privates by firms like Blackstone and TPG.

Management Changes

Stakeholder Impact

• Shareholders: Expected to receive merger consideration upon closing.
• Employees: Transitioning to a private company structure under new ownership.
• Customers/Partners: Continuity of business expected, though under new private ownership.

Next Steps

• Finalize closing conditions for the merger.
• Complete the acquisition on or about April 7, 2026.
• Announce the successor to CEO Stephen P. MacMillan.

Key Dates

Keywords

Hologic, Merger, Blackstone, TPG, Go-private, Stephen MacMillan, Regulatory Approval, Medical Technology